Drug screening model meets cancer organoid technology

Tumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived x...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chen, Qin, Tianyu, Huang, Yuhan, Li, Yuan, Chen, Gang, Sun, Chaoyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451679/
https://www.ncbi.nlm.nih.gov/pubmed/32822897
http://dx.doi.org/10.1016/j.tranon.2020.100840
_version_ 1783575027286802432
author Liu, Chen
Qin, Tianyu
Huang, Yuhan
Li, Yuan
Chen, Gang
Sun, Chaoyang
author_facet Liu, Chen
Qin, Tianyu
Huang, Yuhan
Li, Yuan
Chen, Gang
Sun, Chaoyang
author_sort Liu, Chen
collection PubMed
description Tumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived xenograft (PDX). So, cancer organoid has been widely applied to preclinical drug evaluation, biomarker identification, biological research, and individualized therapy. Besides, cancer organoid can be preserved, resuscitated, passed infinitely, and mechanically cultured on a chip for drug screening; it has become one of the partial models for low/high-throughput drug screening in the preclinical trial in vitro. Therefore, this review presents the recent developments of tumor organoids for drug screening, which will introduce from four aspects, including the stability/credibility, types, application, deficiency and prospect of the tumor organoids model for drug screening.
format Online
Article
Text
id pubmed-7451679
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-74516792020-09-09 Drug screening model meets cancer organoid technology Liu, Chen Qin, Tianyu Huang, Yuhan Li, Yuan Chen, Gang Sun, Chaoyang Transl Oncol Review article Tumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived xenograft (PDX). So, cancer organoid has been widely applied to preclinical drug evaluation, biomarker identification, biological research, and individualized therapy. Besides, cancer organoid can be preserved, resuscitated, passed infinitely, and mechanically cultured on a chip for drug screening; it has become one of the partial models for low/high-throughput drug screening in the preclinical trial in vitro. Therefore, this review presents the recent developments of tumor organoids for drug screening, which will introduce from four aspects, including the stability/credibility, types, application, deficiency and prospect of the tumor organoids model for drug screening. Neoplasia Press 2020-08-18 /pmc/articles/PMC7451679/ /pubmed/32822897 http://dx.doi.org/10.1016/j.tranon.2020.100840 Text en © 2020 Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. CC BY-NC-ND 4.0. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review article
Liu, Chen
Qin, Tianyu
Huang, Yuhan
Li, Yuan
Chen, Gang
Sun, Chaoyang
Drug screening model meets cancer organoid technology
title Drug screening model meets cancer organoid technology
title_full Drug screening model meets cancer organoid technology
title_fullStr Drug screening model meets cancer organoid technology
title_full_unstemmed Drug screening model meets cancer organoid technology
title_short Drug screening model meets cancer organoid technology
title_sort drug screening model meets cancer organoid technology
topic Review article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451679/
https://www.ncbi.nlm.nih.gov/pubmed/32822897
http://dx.doi.org/10.1016/j.tranon.2020.100840
work_keys_str_mv AT liuchen drugscreeningmodelmeetscancerorganoidtechnology
AT qintianyu drugscreeningmodelmeetscancerorganoidtechnology
AT huangyuhan drugscreeningmodelmeetscancerorganoidtechnology
AT liyuan drugscreeningmodelmeetscancerorganoidtechnology
AT chengang drugscreeningmodelmeetscancerorganoidtechnology
AT sunchaoyang drugscreeningmodelmeetscancerorganoidtechnology